Ruggieri-Marone M, Schochat E
Orthophoniste, Faculdade de Medicina do ABC, São Paulo, Brésil.
Rev Laryngol Otol Rhinol (Bord). 2007;128(1-2):41-6.
The aim of this prospective longitudinal study is to research the amplitude of distortion product otoacoustic emissions caused by the ototoxic drugs used, between the end of the administration and from 15 to 40 days after its use.
It was a prospective longitudinal study composed by term and preterm newborns from the Santo André city hospital, in the period from July 2003 to September 2004. The first evaluation occurred on the hospital discharge day. Three groups were evaluated: control group with 33 term and healthy newborns; term study group with 19 term newborns with more than 37 weeks exposed to amikacin and/or vancomycin; and preterm study group with 15 preterm newborns from 32 to 37 weeks exposed to the same ototoxic. The newborns did not present risk factors for hearing loss according to the JCIH, 2000 concomitant to the neonatal infection. All newborns were evaluated at a corrected gestational age greater than 37 weeks. The otoacoustic emissions amplitudes obtained at the hospital discharge were compared to the ones obtained from 15 to 40 days after the discharge.
The otoacoustic emissions amplitudes of the preterm study group were smaller than the amplitudes of the control group and the term study group in both moments of the test. The amplitude of the newborns' otoacoustic emissions increased in the second moment of the test. The otoacoustic emissions amplitudes of the control group in the second moment of the test were similar to the term study group in the first moment of the research.
There are the increase of the distortion product otoacoustic emissions amplitude from the discharge moment until 15 to 40 days after in the post-natal period. The exposure to amikacin and vancomycin on the recommended dose by Neofax, 2003/2004 did not alter the amplitude of the emissions in the newborns without risk indicators concomitant with neonatal infection.
这项前瞻性纵向研究的目的是研究在使用耳毒性药物结束时以及用药后15至40天内，由这些耳毒性药物引起的畸变产物耳声发射的幅度。
这是一项前瞻性纵向研究，研究对象为2003年7月至2004年9月期间圣安德烈市立医院的足月儿和早产儿。首次评估在出院当天进行。共评估了三组：对照组有33名足月儿且健康；足月儿研究组有19名孕周超过37周且接触过阿米卡星和/或万古霉素的足月儿；早产儿研究组有15名孕周在32至37周且接触过相同耳毒性药物的早产儿。根据2000年美国儿科学会听力联合委员会（JCIH）标准，这些新生儿不存在与新生儿感染相关的听力损失风险因素。所有新生儿均在矫正胎龄大于37周时进行评估。将出院时获得的耳声发射幅度与出院后15至40天获得的幅度进行比较。
在测试的两个时间点，早产儿研究组的耳声发射幅度均小于对照组和足月儿研究组。在测试的第二个时间点，新生儿耳声发射的幅度有所增加。测试第二个时间点对照组的耳声发射幅度与研究第一个时间点足月儿研究组的相似。
在出生后，从出院时刻到出院后15至40天，畸变产物耳声发射幅度会增加。按照2003/2004年《新生儿药物手册（Neofax）》推荐剂量接触阿米卡星和万古霉素，并未改变无新生儿感染相关风险指标的新生儿的耳声发射幅度。
